Agile Therapeutics Inc (STU:0AL)
€ 9.83 0 (0%) Market Cap: 7.41 Mil Enterprise Value: 4.63 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 19/100

Q2 2020 Agile Therapeutics Inc Earnings Call Transcript

Aug 11, 2020 / 08:30PM GMT
Release Date Price: €4490 (+2.98%)
Operator

Greetings and welcome to the Agile Therapeutics Second Quarter 2020 Financial Results Call. (Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Mr. Matt Riley, Head of Investor Relations. Thank you, sir. You may begin.

Matthew Riley
Agile Therapeutics, Inc. - Head of IR & Corporate Communications

Hello, everyone, and welcome to today's conference call to discuss our second quarter 2020 financial results.

Before we start, let me remind you that today's call will include forward-looking statements based on current expectations, including statements concerning our outlook for the third and fourth quarters and full year 2020, management's expectations for our future and financial operational performance, our business strategy and commercialization time line, our assessment of the combined hormonal contraceptive market and the potential market share for Twirla, among other statements regarding our plans, prospects and expectations. Such statements represent our judgments as

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot